EA201690650A1 - Солевая форма гидрохлорида для ингибирования ezh2 - Google Patents
Солевая форма гидрохлорида для ингибирования ezh2Info
- Publication number
- EA201690650A1 EA201690650A1 EA201690650A EA201690650A EA201690650A1 EA 201690650 A1 EA201690650 A1 EA 201690650A1 EA 201690650 A EA201690650 A EA 201690650A EA 201690650 A EA201690650 A EA 201690650A EA 201690650 A1 EA201690650 A1 EA 201690650A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hydrochloride
- salt form
- inhibit ezh2
- methyl
- ezh2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
В данном документе обеспечены новые твердые формы гидрохлорида N-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2Н-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида и связанные с ним композиции и способы.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361891786P | 2013-10-16 | 2013-10-16 | |
PCT/US2014/060724 WO2015057859A1 (en) | 2013-10-16 | 2014-10-15 | Hydrochloride salt form for ezh2 inhibition |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201690650A1 true EA201690650A1 (ru) | 2016-10-31 |
EA038869B1 EA038869B1 (ru) | 2021-10-29 |
Family
ID=52828660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690650A EA038869B1 (ru) | 2013-10-16 | 2014-10-15 | Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения |
Country Status (24)
Country | Link |
---|---|
US (3) | US10040782B2 (ru) |
EP (2) | EP4324525A2 (ru) |
JP (2) | JP6608812B2 (ru) |
KR (1) | KR102142177B1 (ru) |
CN (1) | CN105829302B (ru) |
AU (2) | AU2014337300B2 (ru) |
CA (1) | CA2925889C (ru) |
CL (1) | CL2016000866A1 (ru) |
DK (1) | DK3057962T3 (ru) |
EA (1) | EA038869B1 (ru) |
ES (1) | ES2960953T3 (ru) |
FI (1) | FI3057962T3 (ru) |
HU (1) | HUE063984T2 (ru) |
IL (1) | IL244787B (ru) |
LT (1) | LT3057962T (ru) |
MA (1) | MA38949A1 (ru) |
MX (1) | MX2016004703A (ru) |
MY (1) | MY179802A (ru) |
PE (1) | PE20161273A1 (ru) |
PL (1) | PL3057962T3 (ru) |
PT (1) | PT3057962T (ru) |
SG (2) | SG10201901977XA (ru) |
SI (1) | SI3057962T1 (ru) |
WO (1) | WO2015057859A1 (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4190777A1 (en) | 2012-04-13 | 2023-06-07 | Epizyme, Inc. | Hbr salt form for ezh2 inhibition |
MY179802A (en) | 2013-10-16 | 2020-11-16 | Eisai R&D Man Co Ltd | Hydrochloride salt form for ezh2 inhibition |
EP3076977B1 (en) | 2013-12-06 | 2021-03-03 | Epizyme, Inc. | Combination therapy for treating cancer |
PL3157527T3 (pl) | 2014-06-17 | 2023-08-07 | Epizyme, Inc. | Inhibitory ezh2 do leczenia chłoniaka |
AU2015331729A1 (en) | 2014-10-16 | 2017-04-13 | Epizyme, Inc. | Method for treating cancer |
MX2017006089A (es) * | 2014-11-17 | 2017-12-11 | Epizyme Inc | Metodo para tratar el cancer. |
US10456407B2 (en) | 2015-04-20 | 2019-10-29 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2016201328A1 (en) | 2015-06-10 | 2016-12-15 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
US10493076B2 (en) | 2015-08-24 | 2019-12-03 | Epizyme, Inc. | Method for treating cancer |
US11951108B2 (en) | 2016-01-29 | 2024-04-09 | Epizyme, Inc. | Combination therapy for treating cancer |
CA3025933A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
MA45406A (fr) | 2016-06-17 | 2019-04-24 | Epizyme Inc | Inhibiteurs d'ezh2 pour traiter le cancer |
TW201831181A (zh) | 2017-01-19 | 2018-09-01 | 日商第一三共股份有限公司 | 用以用於治療htlv-1相關脊髓病之醫藥組成物 |
WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
JP2020522687A (ja) | 2017-06-02 | 2020-07-30 | エピザイム,インコーポレイティド | 癌を処置するためのezh2阻害剤の使用 |
US11452727B2 (en) | 2017-09-05 | 2022-09-27 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2020011607A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
WO2021035194A1 (en) | 2019-08-22 | 2021-02-25 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
WO2023209591A1 (en) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | N−シアノ−n′−置換−アリールカルボキシイミダミド化合物の製造法 |
WO1995018097A1 (fr) | 1993-12-27 | 1995-07-06 | Eisai Co., Ltd. | Derive de l'acide anthranilique |
DE19516776A1 (de) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin-Regulatorgene |
US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | N−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
AU6060099A (en) | 1998-09-30 | 2000-04-17 | Procter & Gamble Company, The | 2-substituted ketoamides |
UA71587C2 (ru) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Translated By PlajАМИДЫ АНТРАНИЛОВОЙ КИСЛОТЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕЧЕБНЫХ СРЕДСТВ |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
CA2433158C (en) | 2000-12-28 | 2011-05-10 | Shionogi & Co., Ltd. | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor |
US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
JPWO2003070277A1 (ja) | 2002-02-19 | 2005-06-09 | 塩野義製薬株式会社 | 抗掻痒剤 |
TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
JP5160885B2 (ja) | 2004-06-01 | 2013-03-13 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 再構成ヒストンメチルトランスフェラーゼ複合体及びそのモジュレーターの識別方法 |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
US7923219B2 (en) | 2005-06-02 | 2011-04-12 | The University Of North Carolina At Chapel Hill | Ubiquitin E3 ligase |
FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
PL1940821T3 (pl) | 2005-10-19 | 2013-08-30 | Gruenenthal Gmbh | Nowe ligandy receptora waniloidowego i ich zastosowanie do wytwarzania leków |
ATE510822T1 (de) | 2005-10-21 | 2011-06-15 | Merck Sharp & Dohme | Kaliumkanalinhibitoren |
EP1941060B1 (en) | 2005-10-28 | 2012-02-29 | The University of North Carolina At Chapel Hill | Protein demethylases comprising a jmjc domain |
AU2006325746A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
AU2006336552B2 (en) | 2006-01-20 | 2012-12-20 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
CN101443007A (zh) | 2006-05-15 | 2009-05-27 | Irm责任有限公司 | Terephthalamate化合物和组合物及其作为hiv整合酶抑制剂的用途 |
EP2040711A2 (en) | 2006-05-18 | 2009-04-01 | Amphora Discovery Corporation | 2-oxo-1,2-dihydroquinoline derivatives, compositions, and uses thereof as antiproliferative agents |
WO2008108825A2 (en) | 2006-10-10 | 2008-09-12 | Burnham Institute For Medical Research | Neuroprotective compositions and methods |
AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
JP2011502148A (ja) | 2007-10-31 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛の治療用としてのp2x3受容体アンタゴニスト |
AU2008337286B2 (en) | 2007-12-19 | 2014-08-07 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
EP2335779A1 (en) | 2008-08-08 | 2011-06-22 | New York Blood Center | Small Molecule Inhibitors of Retroviral Assembly & Maturation |
FR2934995B1 (fr) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
JP2012522013A (ja) | 2009-03-27 | 2012-09-20 | ザ ユーエービー リサーチ ファウンデーション | 調節ires媒介翻訳 |
WO2011011366A2 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
CA2784899A1 (en) | 2009-12-30 | 2011-07-07 | Avon Products, Inc. | Topical lightening composition and uses thereof |
WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
WO2012005805A1 (en) | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
WO2011140324A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indoles |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
US8895245B2 (en) | 2010-09-10 | 2014-11-25 | Epizyme, Inc. | Inhibitors of human EZH2 and methods of use thereof |
WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2012075080A1 (en) | 2010-12-01 | 2012-06-07 | Glaxosmithkline Llc | Indoles |
RU2013130253A (ru) | 2010-12-03 | 2015-01-10 | Эпизайм, Инк. | 7-деазапуриновые регуляторы метилтрансферазы гистонов и способы их применения |
JP2014511389A (ja) | 2011-02-28 | 2014-05-15 | エピザイム インコーポレイテッド | 置換6,5−縮合二環式ヘテロアリール化合物 |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
KR102587175B1 (ko) | 2012-03-12 | 2023-10-06 | 에피자임, 인코포레이티드 | 인간 ezh2의 억제제 및 이의 사용 방법 |
BR112014025506B1 (pt) | 2012-04-13 | 2024-02-06 | Epizyme, Inc | Composição que compreende composto inibidor de ezh2, uso terapêutico da mesma e método in vitro de inibição da proliferação de células de câncer |
EP4190777A1 (en) | 2012-04-13 | 2023-06-07 | Epizyme, Inc. | Hbr salt form for ezh2 inhibition |
US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
CA2888021A1 (en) | 2012-10-15 | 2014-04-24 | Epizyme, Inc. | Substituted n-((2-oxo-1,2-dihydropyridin-3-yl)-methyl)-benzamide compounds and their use in the treatment of ezh2-mediated disorders |
PL2908823T3 (pl) | 2012-10-15 | 2020-03-31 | Epizyme, Inc. | Sposoby leczenia nowotworu |
CA2894216A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
WO2014100665A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5 |
CA2903572A1 (en) | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
US9624205B2 (en) | 2013-07-19 | 2017-04-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
EP3022184B1 (en) | 2013-07-19 | 2017-09-27 | Epizyme, Inc. | Substituted benzene compounds |
MY179802A (en) | 2013-10-16 | 2020-11-16 | Eisai R&D Man Co Ltd | Hydrochloride salt form for ezh2 inhibition |
-
2014
- 2014-10-15 MY MYPI2016000542A patent/MY179802A/en unknown
- 2014-10-15 LT LTEPPCT/US2014/060724T patent/LT3057962T/lt unknown
- 2014-10-15 US US15/029,848 patent/US10040782B2/en active Active
- 2014-10-15 EP EP23203529.5A patent/EP4324525A2/en active Pending
- 2014-10-15 CN CN201480056428.6A patent/CN105829302B/zh active Active
- 2014-10-15 SI SI201432051T patent/SI3057962T1/sl unknown
- 2014-10-15 EP EP14854272.3A patent/EP3057962B1/en active Active
- 2014-10-15 MX MX2016004703A patent/MX2016004703A/es active IP Right Grant
- 2014-10-15 EA EA201690650A patent/EA038869B1/ru unknown
- 2014-10-15 PT PT148542723T patent/PT3057962T/pt unknown
- 2014-10-15 WO PCT/US2014/060724 patent/WO2015057859A1/en active Application Filing
- 2014-10-15 SG SG10201901977XA patent/SG10201901977XA/en unknown
- 2014-10-15 ES ES14854272T patent/ES2960953T3/es active Active
- 2014-10-15 CA CA2925889A patent/CA2925889C/en active Active
- 2014-10-15 FI FIEP14854272.3T patent/FI3057962T3/fi active
- 2014-10-15 SG SG11201602269QA patent/SG11201602269QA/en unknown
- 2014-10-15 AU AU2014337300A patent/AU2014337300B2/en active Active
- 2014-10-15 PE PE2016000506A patent/PE20161273A1/es unknown
- 2014-10-15 JP JP2016519378A patent/JP6608812B2/ja active Active
- 2014-10-15 KR KR1020167011534A patent/KR102142177B1/ko active IP Right Grant
- 2014-10-15 PL PL14854272.3T patent/PL3057962T3/pl unknown
- 2014-10-15 HU HUE14854272A patent/HUE063984T2/hu unknown
- 2014-10-15 DK DK14854272.3T patent/DK3057962T3/da active
- 2014-10-15 MA MA38949A patent/MA38949A1/fr unknown
-
2016
- 2016-03-28 IL IL244787A patent/IL244787B/en unknown
- 2016-04-13 CL CL2016000866A patent/CL2016000866A1/es unknown
-
2018
- 2018-06-05 US US16/000,539 patent/US10710987B2/en active Active
- 2018-12-11 JP JP2018231817A patent/JP2019052181A/ja active Pending
-
2019
- 2019-04-02 AU AU2019202246A patent/AU2019202246A1/en not_active Abandoned
-
2020
- 2020-06-03 US US16/891,427 patent/US20210017163A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690650A1 (ru) | Солевая форма гидрохлорида для ингибирования ezh2 | |
CY1122883T1 (el) | Ν-((4,6-διμεθυλ-2-οξο-l,2-διυδροπυριδιν-3-υλ)μεθυλ)-5-(αιθυλ (τετραϋδρο-2η-πυραν-4-υλ)αμινο)-4-μεθυλ-4'-(μορφολινομεθυλ)-[l,1'-διφαινυλ]-3-καρβοξαμιδιο υδροβρωμικο για χρηση στη θεραπεια μιας κυτταροπολλαπλασιαστικης διαταραχης του αιματολογικου συστηματος | |
DK3220916T3 (da) | Fremgangsmåde til behandling af cancer med n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamid | |
EA202091186A1 (ru) | ИНГИБИТОРЫ KRas G12C | |
EA201590748A1 (ru) | Противовирусные соединения против rsv | |
EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
EA201690930A1 (ru) | Композиции и способы модуляции фарнезоидных х-рецепторов | |
EA201690752A1 (ru) | Ингибиторы g12c kras | |
BR112015022191A8 (pt) | compostos heteroarila e usos dos mesmos | |
CL2015002814A1 (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos | |
EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
EA201690277A1 (ru) | Производные замещенного глиоксамидом пирроламида и их применение в качестве лекарственных средств для лечения гепатита b | |
EA201690598A1 (ru) | Аминогетероарил бензамиды в качестве ингибиторов киназы | |
EA201690406A1 (ru) | Селективные ингибиторы grp94 и способы их применения | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
EA201790661A2 (ru) | Ингибиторы вируса гепатита c | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
CY1121421T1 (el) | Φαρμακοτεχνικες μορφες | |
EA201692480A1 (ru) | Фармацевтическая композиция | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
EA201690844A1 (ru) | Ингибиторы gsk-3 | |
EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения |